K. R. Martin, D. Wu, M. Meydani // Atherosclerosis. – 2000. – Vol. 150, № 2. –
P. 265-274.
228.
Masuo K. Obesity-related hypertension: role of the sympathetic nervous
system, insulin, and leptin / K. Masuo // Curr. Hypertens. Rep. – 2002. – Vol. 4. –
P. 112–118.
229.
McNeely W. Sibutramine: a review of its contribution to the management of
obesity / W. McNeely, K. L. Goa // Drugs. – 1998. – Vol. 56. – P. 1093-1124.
230.
McNeely W. Sibutramine: a review of its contribution to the management of
obesity / W. McNeely, K. L. Goa // Drugs. – 1998. – Vol. 56. – P. 1093-1124.
231.
Mechanisms of antihyperglycemic effects of moxonidine in the obese
spontaneously hypertensive Koletsky rats / P. Ernsberger [et al.] // J. Pharmacol.
Exp Therap. – 1999. – Vol. 288, № 1. – P. 139-147.
232.
Messerli F. Moxonidine: a new and versatile antihypertensive / F. Messerli // J.
Cardiovasc. Pharmacol. – 2005. – Vol. 35, № 7, № 4. – P. 53-56.
233.
Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular
events: the Northern Manhattan Study (NOMAS) / T. Suzuki [et al.] // Am. Heart.
J. – 2008. – Vol. 156, № 2. P. 405-410.
234.
Metabolic Syndrome, Inflammation and Atherosclerosis / R. Paoletti [et al.] //
Vasc. Health. Risk. Manag. – 2006. – Vol. 2, № 2. – P. 145-152.
235.
Clinical features and up-to-date therapy of hypertensive
emergencies // F. P.
/
– 2004. – Vol. 129, № 14.
– P. 768.
236.
Michel M. C. α-and β-adrenoceptors in hypertension: molecular biology and
pharmacological studies / M. C. Michel, T. Philipp, O. E. Brodde // Pharmacol.
Toxicol. – 1992. – Vol. 70, № 2. – P. 1-10.
237.
Mizutani K. Biomechanical properties and chemical composition of the aorta
in genetic hypertensive rats / K. Mizutani [et al.] // J. Hypertens. – 1999. – Vol.
17. – P. 481-487.
